Heinz E Moser

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6230068/publications.pdf

Version: 2024-02-01

49	5,228	270111	263392
papers	citations	25 h-index	45 g-index

53	53	53	4462
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Discovery and Optimization of DNA Gyrase and Topoisomerase IV Inhibitors with Potent Activity against Fluoroquinolone-Resistant Gram-Positive Bacteria. Journal of Medicinal Chemistry, 2021, 64, 6329-6357.	2.9	14
2	Towards the sustainable discovery and development of new antibiotics. Nature Reviews Chemistry, 2021, 5, 726-749.	13.8	439
3	Topoisomerase Inhibitors Addressing Fluoroquinolone Resistance in Gram-Negative Bacteria. Journal of Medicinal Chemistry, 2020, 63, 7773-7816.	2.9	24
4	Challenges of antibacterial drug discovery. Arkivoc, 2020, 2019, 227-244.	0.3	11
5	Optimization of LpxC Inhibitors for Antibacterial Activity and Cardiovascular Safety. ChemMedChem, 2019, 14, 1560-1572.	1.6	58
6	Size Matters and How You Measure It: A Gram-Negative Antibacterial Example Exceeding Typical Molecular Weight Limits. ACS Infectious Diseases, 2019, 5, 1688-1692.	1.8	20
7	Biased Complement Diversity Selection for Effective Exploration of Chemical Space in Hit-Finding Campaigns. Journal of Chemical Information and Modeling, 2019, 59, 1709-1714.	2.5	9
8	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae â€“ Identification of LYS228. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 748-755.	1.0	48
9	Synthesis and Microbiological Evaluation of Novel Tetracyclic Fluoroquinolones. ChemMedChem, 2017, 12, 1687-1692.	1.6	20
10	Antiviral Nucleotide Incorporation by Recombinant Human Mitochondrial RNA Polymerase Is Predictive of Increased In Vivo Mitochondrial Toxicity Risk. Antimicrobial Agents and Chemotherapy, 2016, 60, 7077-7085.	1.4	18
11	Exploring the active site of the Streptococcus pneumoniae topoisomerase IVâ€“DNA cleavage complex with novel 7,8-bridged fluoroquinolones. Open Biology, 2016, 6, 160157.	1.5	19
12	Antibacterial Activity of Enrofloxacin and Ciprofloxacin Derivatives of Î²â€Octaarginine. Chemistry and Biodiversity, 2015, 12, 179-193.	1.0	18
13	Aminoglycosides. , 2012, , 229-269.		23
14	Synthesis and Spectrum of the Neoglycoside ACHN-490. Antimicrobial Agents and Chemotherapy, 2010, 54, 4636-4642.	1.4	214
15	New aminoglycoside antibiotics. Expert Opinion on Therapeutic Patents, 2010, 20, 1321-1341.	2.4	52
16	The Identification of Indacaterol as an Ultralong-Acting Inhaled Î²₂-Adrenoceptor Agonist. Journal of Medicinal Chemistry, 2010, 53, 3675-3684.	2.9	90
17	Physicochemical Properties of Antibacterial Compounds: Implications for Drug Discovery. Journal of Medicinal Chemistry, 2008, 51, 2871-2878.	2.9	582
18	Potent and selective xanthine-based inhibitors of phosphodiesterase 5. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 2376-2379.	1.0	10

#	Article	IF	Citations
19	Pharmacokinetics in Animals and Humans of a First-in-Class Peptide Deformylase Inhibitor. Antimicrobial Agents and Chemotherapy, 2004, 48, 4835-4842.	1.4	51
20	DNA binding ligands targeting drug-resistant Gram-positive bacteria. Part 1: Internal benzimidazole derivatives. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 1253-1257.	1.0	119
21	DNA binding ligands targeting drug-resistant Gram-positive bacteria. Part 2: C-terminal benzimidazoles and derivatives. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 1259-1263.	1.0	56
22	DNA Binding Ligands Targeting Drug-Resistant Gram-Positive Bacteria. Part 1. Internal Benzimidazole Derivatives. ChemInform, 2004, 35, no.	0.1	0
23	DNA Binding Ligands Targeting Drug-Resistant Gram-Positive Bacteria. Part 2. C-Terminal Benzimidazoles and Derivatives. ChemInform, 2004, 35, no.	0.1	0
24	DNA binding ligands with in vivo efficacy in murine models of bacterial infection: optimization of internal aromatic amino acids. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 2067-2072.	1.0	21
25	Macrocyclic Inhibitors for Peptide Deformylase:Â A Structureâ^'Activity Relationship Study of the Ring Size. Journal of Medicinal Chemistry, 2004, 47, 4941-4949.	2.9	49
26	DNA Binding Ligands with Improved in Vitro and in Vivo Potency against Drug-ResistantStaphylococcus aureus. Journal of Medicinal Chemistry, 2004, 47, 4352-4355.	2.9	27
27	DNA Binding Ligands Targeting Drug-Resistant Bacteria:â€‰ Structure, Activity, and Pharmacology. Journal of Medicinal Chemistry, 2003, 46, 3914-3929.	2.9	67
28	Pharmacology of Novel Heteroaromatic Polycycle Antibacterials. Antimicrobial Agents and Chemotherapy, 2003, 47, 3448-3457.	1.4	19
29	In Vitro Antimicrobial Activity of GSQ1530, a New Heteroaromatic Polycyclic Compound. Antimicrobial Agents and Chemotherapy, 2002, 46, 3168-3174.	1.4	26
30	A solid-phase approach towards the synthesis of PDE5 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 1973-1976.	1.0	17
31	DNA Binding Ligands with Excellent Antibiotic Potency Against Drug-Resistant Gram-Positive Bacteria. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 2591-2594.	1.0	37
32	8-Aryl xanthines potent inhibitors of phosphodiesterase 5. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 2587-2590.	1.0	22
33	Distribution of a 20-mer phosphorothioate oligonucleotide, CGP69846A (ISIS 5132), into airway leukocytes and epithelial cells following intratracheal delivery to brown-norway rats. Pharmaceutical Research, 1999, 16, 1542-1549.	1.7	7
34	Solid-Phase Synthesis of 2,4,6-Triaminopyrimidines. Chemistry - A European Journal, 1999, 5, 3450-3458.	1.7	23
35	Dual Recognition of Double-Stranded DNA by 2â€²-Aminoethoxy-Modified Oligonucleotides. Angewandte Chemie - International Edition, 1998, 37, 1288-1291.	7.2	131
36	Creating RNA Bulges:Â Cleavage of RNA in RNA/DNA Duplexes by Metal Ion Catalysisâ€. Biochemistry, 1996, 35, 16591-16600.	1.2	81

#	Article	IF	Citations
37	Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 15481-15484.	3.3	136
38	Sequence-Specific Cleavage of RNA Using Lanthanide Complexes Linked to Oligonucleotides. , 1996, , 307-320.		3
39	The evaluation of 2â€²- and 6â€²-substituted carbocyclic nucleosides as building blocks for antisense oligonucleotides. Bioorganic and Medicinal Chemistry Letters, 1995, 5, 431-436.	1.0	23
40	Sequence analysis of phosphorothioate oligonucleotides via matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 1995, 13, 1195-1203.	1.4	40
41	Antisense Oligonucleotides. Accounts of Chemical Research, 1995, 28, 366-374.	7.6	441
42	A novel fluorogenic substrate for ribonucleases. Synthesis and enzymatic characterization. Nucleic Acids Research, 1994, 22, 2731-2739.	6.5	23
43	An Efficient Total Synthesis of Carbocyclic 2?-Deoxyribonucleosides. Helvetica Chimica Acta, 1994, 77, 1527-1540.	1.0	12
44	Efficient sequence-specific cleavage of RNA using novel europium complexes conjugated to oligonucleotides. Chemistry and Biology, 1994, 1, 185-190.	6.2	94
45	The influence of protecting groups on lipase catalyzed transesterifications: Enzymatic resolution of racemic cis-1,3-cyclopentanediol derivatives. Tetrahedron Letters, 1993, 34, 2923-2926.	0.7	16
46	Matrix-assisted laser desorption ionization time-of-flight mass spectrometry: a powerful tool for the mass and sequence analysis of natural and modified oligonucleotides. Nucleic Acids Research, 1993, 21, 3191-3196.	6.5	466
47	Double strand cleavage of genomic DNA at a single site by triple helix formation. Journal of the American Chemical Society, 1988, 110, 7927-7929.	6.6	128
48	Sequence-specific cleavage of double helical DNA by triple helix formation. Science, 1987, 238, 645-650.	6.0	1,389
49	Poly(dipeptamidinium)-Salze: Definition und Methoden zur prÃparativen Herstellung. Helvetica Chimica Acta, 1986, 69, 1224-1262.	1.0	32